{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"147.87","value":"295.96"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"100"}],"units":"Participants"}],"title":"Cycle(C) 1 Day(D) 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"46.99","value":"215.97"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"}],"units":"Participants"}],"title":"C1D8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"33.13","value":"208.91"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"102"}],"units":"Participants"}],"title":"C1D15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.36","value":"99.61"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"103"}],"units":"Participants"}],"title":"C2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"65.45","value":"103.29"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"101"}],"units":"Participants"}],"title":"C3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.90","value":"99.26"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"101"}],"units":"Participants"}],"title":"C4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.48","value":"98.46"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"100"}],"units":"Participants"}],"title":"C5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.18","value":"99.10"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"102"}],"units":"Participants"}],"title":"C6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.61","value":"98.84"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"}],"units":"Participants"}],"title":"C7"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.12","value":"95.68"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"title":"C8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.08","value":"97.64"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"83"}],"units":"Participants"}],"title":"Maintenance Week 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.49","value":"96.78"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"}],"units":"Participants"}],"title":"Maintenance Week 9"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.66","value":"97.77"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"48"}],"units":"Participants"}],"title":"Maintenance Week 17"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.23","value":"97.16"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"title":"Maintenance Week 25"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.27","value":"95.08"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"title":"Maintenance Week 33"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.26","value":"95.77"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"title":"Maintenance Week 41"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.48","value":"93.56"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"title":"Maintenance Week 49"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.95","value":"93.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"title":"Maintenance Week 57"}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"}],"units":"Participants"}],"description":"The duration of obinutuzumab administration (in minutes) by cycle was defined as the difference between the end time and the start time of obinutuzumab administration.","dispersionType":"Standard Deviation","groups":[{"description":"Participants were enrolled in an induction phase and received 6-8 cycles of obinutuzumab, combined with 6 or 8 cycles of standard chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone/methylprednisolone \\[CHOP - 21-day cycle) or bendamustine (28-day cycle), or cyclophosphamide, vincristine, and prednisone/prednisolone/methylprednisolone \\[CVP - 21-day cycle\\]). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. The investigator was free to choose the chemotherapy for each participant.","id":"OG000","title":"All Participants"}],"paramType":"MEAN","populationDescription":"The safety population included all participants who received at least one dose of obinutuzumab.","reportingStatus":"POSTED","timeFrame":"All cycles including maintenance (1 cycle: 21 or 28 days depending on the chemotherapy selected; up to approximately 2.5 years)","title":"Duration (In Minutes) of Obinutuzumab Administration by Cycle","type":"SECONDARY","unitOfMeasure":"Minutes"}